Ambryon Biosciences

LCAR-B38M Cells in Treating Relapsed/Refractory (R/R) Multiple Myeloma

Single-arm phase 1/2 trial (LEGEND-2) of LCAR-B38M, a dual-epitope BCMA CAR-T cell therapy, in 74 patients with relapsed or refractory multiple myeloma: 87.8% responded, 73.0% had a complete response, and 5-year overall survival was 49.1%.

StatusUnknown
PhasePhase 1 2
Primary Endpoint ResultInconclusive
Enrollment100
Start Date2015-10-02
Primary Completion Date2023-12-31

Results Summary

No results are posted on ClinicalTrials.gov; the numbers below come from three LEGEND-2 papers. The registered primary outcome was treatment-related adverse events. In the first report (57 patients at one site, cutoff 6 February 2018, median follow-up 8 months), 50 of 57 responded (88%) and 39 of 57 (68%) had a complete response. At the 4-year report (74 patients, cutoff 25 May 2021, median follow-up 47.8 months), the overall response rate was 87.8%, 54 of 74 (73.0%) had a complete response, median progression-free survival was 18.0 months and median overall survival was not reached. Cytokine release syndrome occurred in 68 of 74 (91.9%), grade 3 or higher in 7 (one fatal); one patient had grade 1 neurotoxicity. At the 5-year report (cutoff 30 November 2022, median follow-up 65.4 months), progression-free survival was 21.0% and overall survival 49.1% at 5 years; 12 of 74 (16.2%) were relapse-free. Second primary solid tumors occurred in 4 of 74 (5.4%).

Design Implications

A BCMA CAR with two single-domain antibodies on different epitopes gave deep responses at a median of only 0.5 million CAR+ cells/kg; the authors attribute this to higher avidity, but no single-epitope comparator was tested, so the benefit of dual binding is a hypothesis. Remissions were durable in a minority: progression continued past 5 years, depth of response (complete response, MRD negativity) predicted survival, and extramedullary disease predicted early relapse, so designs for these patients need a way to deepen or consolidate response, for example maintenance therapy. CAR-T cells persisted for a median of 280 days and persistence did not predict durable remission. Re-treatment with another anti-BCMA CAR-T worked in only 5 of 16 patients, while proteasome inhibitor regimens worked in 16 of 20, so a second CAR-T infusion against the same target is a weak option after relapse.

Rationale

LCAR-B38M is an autologous T-cell product transduced with a lentiviral vector that encodes a chimeric antigen receptor against B cell maturation antigen (BCMA, gene TNFRSF17). BCMA is a TNF-receptor-family protein on myeloma plasma cells that is needed for plasma cell survival, with low expression on normal cells and none on CD34+ hematopoietic cells. The receptor joins two llama-derived single-domain antibodies that bind two different BCMA epitopes to a CD8a hinge and transmembrane domain and a 4-1BB/CD3 zeta signaling domain. Binding two epitopes was expected to raise avidity and allow responses at low cell doses in patients whose myeloma had relapsed after standard drugs.

Limitations

Single-arm, open-label, no control group; 74 patients treated at four Chinese centers, each with its own lymphodepletion and infusion schedule. The registered primary outcome (adverse events) has no success criterion and no results are posted. The trial was registered retrospectively as phase 1/2 with 100 planned patients, while the papers call it phase 1. Response and survival are investigator-assessed.

Registry record

This is a single arm, open-label, multi-center, phase 1/2 study, to determine the safety and efficacy of LCAR-B38M CAR-T cells in treating patients diagnosed with refractory/relapsed multiple myeloma (r/r MM).

Primary OutcomesOccurrence of treatment related adverse events as assessed by CTCAE v4.0
Keywordsmultiple myeloma, BCMA, CAR-T
Registry Last Updated2023-06-12
Minimum Age18 Years
Modalitiescell_therapy
Maximum Age80 Years
Intervention NamesLCAR-B38M CAR-T cell injection
AllocationNot Applicable
MaskingNone
Primary PurposeTreatment
Has ResultsNo
AcronymLEGEND-2
Enrollment TypeEstimated
Intervention Typesbiological
Study TypeInterventional
Intervention ModelSingle Group
Healthy VolunteersNo
Condition TermsRefractory or Relapsed Multiple Myeloma, Multiple Myeloma
Completion Date2023-12-31
Lead Sponsor ClassIndustry
Eligibility SexAll

Official Title

A Clinical Study of Legend Biotech BCMA-chimeric Antigen Receptor Technology in Treating Relapsed/Refractory (R/R) Multiple Myeloma Patients

Eligibility Criteria

Inclusion Criteria:

  • Patients must have a confirmed prior diagnosis of active multiple myeloma as defined by the updated IMWG criteria.
  • Patients with refractory multiple myeloma. Clear BCMA expression must be detected on malignant plasma cells from either bone marrow or a plasmacytoma by flow cytometry or immunohistochemistry.
  • Refractory disease:1) At least 3 prior regimens, which must at least have contained bortezomi. or 2) other circumstances identified by clinical doctors.
  • Relapse criteria in NCCN clinical practice guidelines in Oncology: Multiple Myeloma (2016.V2)

Exclusion Criteria:

  • Women of child-bearing potential or who are pregnant or breastfeeding.
  • Have any active and uncontrolled infection: hepatitis B, hepatitis C, HIV, or other fatal viral and bacterial infection.
  • Systemic corticosteroid steroid therapy of greater than 5 mg/day of prednisone or equivalent dose of another corticosteroid are not allowed within 2 weeks prior to either the required leukapheresis or the initiation of the conditioning chemotherapy regimen.
  • Patients with any uncontrolled intercurrent illness or serious uncontrolled medical disorder.
  • Patients with CNS metastases or symptomatic CNS involvement (including cranial neuropathies or mass lesions and spinal cord compression).
  • History of allogeneic stem cell transplantation. Have active acute or chronic graft-versus-host-disease (GVHD), or require immunosuppressant medications for GVHD, within 6 months of enrollment.
  • Patients with active autoimmune skin diseases such as psoriasis or other active autoimmune diseases such as rheumatoid arthritis.

Identifiers & revision